Therapeutic Implications of Immunogenic Cell Death in Human Cancer by Fabio Palombo et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PERSPECTIVE ARTICLE
published: 06 January 2014
doi: 10.3389/fimmu.2013.00503
Therapeutic implications of immunogenic cell death in
human cancer
Fabio Palombo1*, Chiara Focaccetti 1 andVincenzo Barnaba1,2*
1 Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy
2 Istituto Pasteur – Fondazione Cenci Bolognetti, Rome, Italy
Edited by:
Kristian Michael Hargadon,
Hampden-Sydney College, USA
Reviewed by:
Junko Matsuzaki, Roswell Park
Cancer Institute, USA
Walter J. Storkus, University of
Pittsburgh, USA
*Correspondence:
Fabio Palombo and Vincenzo Barnaba,
Dipartimento di Medicina Interna e
Specialità Mediche, Sapienza
Università di Roma, viale del
Policlinico 155, Rome 00161, Italy
e-mail: fabio.palombo@uniroma1.it ;
vincenzo.barnaba@uniroma1.it
Dendritic cells (DCs) are central to the adoptive immune response, and their function is reg-
ulated by diverse signals in a context-specific manner. Different DCs have been described in
physiologic conditions, inflammation, and cancer, prompting a series of questions on how
adoptive immune responses, or tolerance, develop against tumors. Increasing evidence
suggests that tumor treatments induce a dramatic change on tumor-infiltrating lymphocytes
and, in particular, on some DC subtypes. In this review, we summarize the latest evidence
on the role of DCs in cancer and preliminary evidence on chemotherapy-associated antigens
identified in human cancers.
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INTRODUCTION
Cancer is characterized not only by abnormal cell growth but also
by increased and diverse modality of cell death, which is sensed by
innate immune cells including macrophages and dendritic cells
(DCs). Dying cells can trigger either tissue homeostatic clear-
ance by macrophages or processing by DCs, which can integrate
signals from dying cells for presentation to T cells in an immuno-
genic or tolerogenic manner. It is well known that antigen-specific
CD4+ and CD8+ T cells are detected in advanced tumor stages
and that adoptive T-cell transfer can be very effective in cancer
therapy (1).
Dendritic cells are essential in priming T-cell responses upon
the processing and presentation of both exogenous antigens,
which are preferentially presented on major histocompatibility
complex (MHC) class II molecules to CD4+ T cells, and endoge-
nous antigens, which are preferentially presented on MHC class
I molecules to CD8+ T cells. The capacity of DCs to present
exogenous antigens derived from other cells (usually necrotic or
apoptotic cells) or soluble antigens on class I molecules is defined
as cross-presentation (2, 3). Different types of DCs have been
described according to different parameters, including where they
are located, the type of antigen they present, and their ability
to present antigens to T cells (4). From a simplified view, DCs
travel in periphery tissues in search of potential antigens that are
derived from pathogen-infected cells (foreign antigens); cancer
cells re-expressing developmental antigens, for which the immune
tolerance is low; or cancer cells expressing mutated proteins as
a consequence of the oncologic process. They are attracted in
inflamed tissue by metabolic products of cell death such as ATP, or
they can be guided by chemokines secreted by innate immune cells
such as macrophages. During the journey, they are characterized
as having a high phagocytic capacity and a low antigen-presenting
capacity: this status is referred to as an immature state. Different
stimuli associated with bacterial or viral infections or damage
signals can then activate DCs. In lymphoid tissues, DCs present
antigens to B and T cells to initiate an adaptive immune response,
depending on the presence of mature signals that direct adoptive
responses.
Pathogen-associated molecular patterns (PAMPs) were first
postulated by Janeway (5) and then identified in different species
including insects. At the core of Janeway’s hypothesis was the
idea that similar structures are shared by different pathogens and
that immune receptors [pattern recognition receptors (PRRs)]
expressed by several types of innate immune cells have evolved
to recognize them. On the same line of reasoning, it became clear
that immune cells can be activated by damage (danger) signals,
which share the properties of being undetectable to immune sen-
sors during physiologic processes and being detectable in cases
of injury. With a few exceptions (e.g., the association of cervix
tumors with the papillomavirus, or of hepatocellular carcinoma
with hepatitis B or C viruses), most tumors deregulate cell life
usually in the absence of a non-self signal however, they can acti-
vate immune responses through danger signals that are referred to
as, in analogy with PAMPs, damage-associated molecular patterns
(DAMPs).
Dendritic cells carry out several complex tasks including anti-
gen sampling in the periphery, cell maturation in the spleen and
lymph nodes, and the critical decision-making process between
immunity and tolerance (lack of immune response). These tasks
are executed by DCs through a remarkable plasticity and an ability
to integrate signals from a variety of receptors sensing extracel-
lular and intracellular environments. This sophisticated system
likely evolved in vertebrates as a way in which to avoid autoim-
mune diseases mediated by adaptive immunity; however, it can
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limit an effective immune response against tumors, which derive
from the self.
HUMAN AND MOUSE DCs IN PHYSIOLOGY AND CANCER
Human and mouse DCs are classified as classical DCs (cDCs)
and plasmacytoid DCs (pDCs) (6) and present different mor-
phologies: pDCs are round shaped, whereas cDCs have dendrites,
distinct membrane markers, and different functions, and derive
from different precursors within the myeloid lineage. This intri-
cately connected system has made it difficult to distinguish DCs
from other myeloid cells. To resolve this issue in mice, DC sub-
types have been characterized through genetic ablation of key
genes, transfer of purified cells, and functional studies. Tradi-
tionally, cDCs have been identified in mice by CD11c expression
(7). However, depletion of cells expressing this marker resulted in
ablation of not only cDCs but also pDCs (8). To obtain a more
precise picture of DC populations, lineage-specific transcription
factors have been identified [reviewed in Ref. (4)]. Two transcrip-
tion factors, Flt3 and Xcr1, are associated with murine DCs, but
not with macrophages, which is in line with their function during
DC development. However, expression of transcription factors can
be tissue specific. For instance, Zbtb46 distinguishes cDCs from
other myeloid and lymphoid cells, but it is downregulated after
DC stimulation; it is also found on endothelial cells, early ery-
throid progenitors, and monocytes stimulated with granulocyte
macrophage-colony stimulating factor (GM-CSF) and interleukin
4 (IL-4). Mouse cDCs in lymphoid tissues are divided into CD8+
and CD4+ T cells and functionally classified according to anti-
gen presentation on MHC class I to CD8 T cells and class II to
CD4 T cells, respectively (4). Importantly, CD8+ cDCs carry out
the unique function of cross-presentation of exogenous antigens
on class I molecules (2, 3). More recently, mouse cDC lineage
has been further refined using expression history of DNGR-
1 gene (9). Transfer of precursor DCs expressing DNGR-1 in
mice depleted of myeloid cells leads to the development of cDCs
but not to pDCs, as observed in the transfer of unfractionated
precursor DCs.
In humans, myeloid cDCs can be categorized as CD1c+
(BDCA1+) and CD11a+ CD141+ (BDCA3+) DCs. The latter cells
have been considered equivalent to mouse CD8+ DCs, partic-
ularly because they express the C-type lectin receptor CLEC9A,
which mediates the uptake of necrotic or dead cells and the
cross-presentation of the related antigens (10). However, recent
evidence from a systematic study of DC populations showed that
the functional specialization of human DCs is completely different
from that of murine DCs (11). In contrast to the murine models,
all human DC populations tested (BDCA1+ or BDCA3+ cDCs,
and even BDCA2+ pDCs) express similar functions including
cross-presentation and capacity of antigen transfer from phagoen-
dosomes into the cytosol. In addition, Toll-like receptors (TLRs)
are expressed differently by human and mouse cDC populations:
both human and mouse cDCs express TLR1, 2, 3, 4, 5, 6, and 8,
whereas TLR11, TLR12, and TLR13 are expressed only by mouse
cDCs, and TLR 10 is unique to humans (12).
Plasmacytoid DCs represent a small fraction of DCs and have
a round shape that is similar to antibody-secreting plasma cells.
Regarding surface markers, pDCs are distinguished from cDCs
by the expression of B220, Siglec-H, and Bst2 in mice and of
BDCA2 (CD303) in humans (4). In both humans and mice,
pDCs express TLR7 and 9 (13, 14). TLR7, 8, and 9 belong to a
functional subfamily and detect PAMPs in endosomal/lysosomal
compartments following acidification [reviewed in Ref. (15)].
After exposure to synthetic TLR7 or TLR9 agonists [e.g., imidazo-
quinoline compounds or guanosine analogs for TLR7/8, cytosine-
phosphorothioate-guanine-oligodeoxynucleotides (CpG-ODNs)
for TLR9], pDCs secrete interferon alpha and proinflammatory
cytokines (IL-8 and tumor necrosis factor alpha) and undergo
maturation, a differentiation program characterized by upregu-
lation of the costimulatory molecules CD80, CD86, and CD40;
expression of functional CC-chemokine receptor 7 (CCR7) and
the maturation marker CD83; and heightened T-cell stimulatory
capacity [reviewed in Ref. (15)]. The transcription factor E2-2 is
essential for pDC development in both mice and humans (16).
It controls the expression of pDC markers directly (e.g., TLR7,
TLR9, BDCA2) and its deletion in mature pDCs, redirecting them
toward the cDC phenotype. In contrast to cDCs, mouse pDCs are
not phagocytic, and they maintain a high turnover of MHC class
II, thus limiting their capacity as professional antigen-presenting
cells (15).
More recently, a new DC subset defined as inflammatory
DCs (infDCs) has been described in inflamed human tissues,
including ascites of ovarian cancer (OC) and breast cancer (17).
InfDCs (CD14+ CD16− BDCA1+) in cancer ascites were sepa-
rated from macrophages (CD14+ CD16c+ BDCA1−) and then
further characterized for the expression of additional markers
(CD11c+ CD11b+ HLA-DR+ BDCA1+ CD206+). InfDCs were
identified in inflamed tissue but not in tumor-draining lymph
nodes with the exception of gastric cancer, which is known to
be associated with persistent chronic inflammation. Molecular
profiling of the purified infDCs revealed a close similarity with
monocyte-derived DCs. These cells induce a Th17 differentia-
tion in vitro and express two lineage-specific transcription factors,
ZBTB46 and CSFR1, which were previously identified in mouse
infDCs. Functional assays showed that infDCs could stimulate
memory CD4+ T cells from the same ascites to produce IL-17,
likely by the secretion of IL-1β, IL-6, and IL-23, which are Th17
cell-polarizing cytokines (17).
Tumors can dramatically influence DC functions [reviewed in
Ref. (6)]. It is well known that tumor-derived DCs are ineffective
in stimulating an immune response and that this ineffectiveness
may contribute to tumor evasion of immune recognition. Tumor-
released factors can induce an altered myelopoiesis that leads to
the release of immature myeloid cells, which, within the tumor
bed, give rise to myeloid-derived suppressor cells (MDSCs). These
findings, which have been confirmed in clinical studies, indicate a
decreased presence and a defective functionality of mature DCs in
patients with breast cancer (18), non-small cell lung cancer (19),
pancreatic cancer (20), cervical cancer (21), hepatocellular carci-
noma (22), and glioma (23). The fate of MDSCs has been investi-
gated in various tumor types in relation to tumor drugs of different
chemical nature including classical chemostatic agents, kinase
inhibitors, and therapeutic antibodies. Pharmacological interven-
tions, however, showed a marginal impact on DCs with respect to
macrophages, which were skewed from an M2 (protumorigenic)
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toward an M1 (anti-tumor) phenotype. Differentiation toward
proinflammatory DCs was induced by vascular endothelial growth
factor inhibitors (24) or blockers of chemokines (25).
How the immune system senses tumors is not as well defined as
for non-self-antigen recognition. The danger theory proposes that
detection of stressed or damaged cells by DCs is a driving force of
adaptive immune responses, irrespective of the level of mutation
frequency of a given tumor (26).
CANCER THERAPY, DC ACTIVATION, IMMUNE RESPONSES,
AND DISCOVERY OF TUMOR ANTIGENS
Cancer is inevitably treated with different drugs that vary either
in the mechanism of action (ranging from the original chemo-
static alkylating agents to pathway-specific inhibitors) or in their
chemical nature (small-molecule drugs, neutralizing antibodies,
cancer vaccines, etc.). The ever-growing arsenal of context-specific
anti-tumor drugs is likely to be applied in unpredicted tumor
cases thanks to technical progress in global genome sequencing,
for which low prices have made it almost an affordable diagnos-
tic approach. The most utilized therapeutic approaches, however,
remain those based on cytotoxic chemotherapy. Although it is well
known that these drugs induce lymphopenia, it is becoming more
and more appreciated that a subset of them also induces a series
of DAMPs, which are recognized by PRRs on innate immune cells
(Figure 1).
Damage-associated molecular patterns such as ATP and high
mobility group box 1 protein (HMGB1) are secreted or released,
whereas others such as calreticulin (CRT) and heat shock protein
90 are exposed de novo or become enriched on the outer leaflet
of the plasma membrane (27) (Figure 1). In addition, DAMPs
are produced as end-stage degradation products such as uric acid
during the course of cell death. Most of these molecules have pre-
dominantly non-immunological functions inside the cell before
their exposure on the cell surface or their secretion (28).
The group of Kroemer and Zitvogel (29) found that treatment
with anthracycline in mice induces immunogenic cell death (ICD),
which is mediated by CRT exposure on apoptotic cells (Figure 1).
Researchers have also reported that timing of CRT exposure with
respect to apoptotic markers and morphological changes is crit-
ical during ICD and that it usually anticipates apoptotic signs
(29, 30). This is a structured process that occurs through different
pathways including RNA-dependent protein kinase-like endoplas-
mic reticulum kinase (PERK)-mediated eIF2α phosphorylation,
the secretory pathway, and caspase 8-mediated B-cell receptor-
associated protein 31 (BCAP31)-dependent activation of BAX and
BAK proteins (31).
An additional DAMP signal released during ICD is the HMGB1
(Figure 1). Preclinical studies have highlighted the importance
of TLR4 activation mediated by HMGB1 binding. Research has
shown that depletion of HMGB1 in mouse xenograft tumors pre-
vents anthracycline-induced anti-tumor activity, which is restored
by exogenous recombinant HMGB1 protein. Clinical studies in
breast cancer have showed that a correlation exists between
the presence of a single nucleotide polymorphism in the TLR4
gene, which prevents the binding of HMGB1 to TLR4, and early
relapse after anthracycline treatment (32, 33). However, the role of
HMGB1 can be context-specific, depending on the oxidation state:
reduced HMGB1 performs as a chemoattractant DAMP, whereas
the fully oxidized form is inactive (34, 35).
A recent paper by Ma and colleagues (36) has identified the
cellular mediator of ICD to be specific inflammatory DC-like
cells in mice. In particular, monocytes recruited into the tumor
bed skewed toward a DC phenotype, which includes expression
of inflammatory DC markers (CD11c+CD11b+Ly6Chi). Tumors
treated with mitoxantrone are infiltrated by CD11c+CD11b+
Ly6Chi cells within 12 h of treatment and later by macrophages.
This early infiltrate is responsible for the tumor-specific CD8+ T-
cell response and anti-tumor activity, as these effects are abrogated
by local expression of ATP-degrading enzyme CD39, pharmaco-
logical blockage of purinergic receptors, and neutralizing antibody
against CD11. The extracellular release of ATP is used not only in
different pathways, such as survival, death, adhesion, proliferation,
differentiation, and mobility, but also as a “find-me signal” from
apoptotic cells, which attract monocytes expressing purinergic
receptors (Figure 1). Release of ATP during the apoptotic process
is mediated by autophagy, which is induced by some chemother-
apy treatments. Research has shown that knockdown of essential
autophagy genes (ATG5, ATG7, and BECN1) reduces ATP secre-
tion in apoptotic cells treated with anthracycline and results in
reduced anti-tumor activity in vivo (37, 38). Apparently, ATP
affects DCs by acting on two pathways. ATP, at a concentration of
about 1µM binds and activates P2Y2 receptor that induces mono-
cyte attraction. At concentrations higher than 30µM,ATP binds to
P2×7 receptor and activates NALP3-ASC-inflammasome, induc-
ing secretion of IL-1β, which skews antigen presentation to CD8+
T cells toward a Th-1 phenotype. The different activation thresh-
old of P2×7 and P2Y2 receptors fits with a migratory/activation
model, where low ATP concentrations in the periphery stimulate
monocyte migration and higher ATP concentrations in the tumor
bed induce DC differentiation.
The ICD concept presents new questions and challenges. Most
of the mouse tumor models used to investigate ICD in vivo were
based on tumor cell lines that did not evolve under an immuno-
logical pressure but rather were expanded in vitro. By contrast,
the efficacy of immunogenic chemotherapy, such as the combina-
tion of oxaliplatin and doxorubicin, in spontaneous mouse tumor
models has been shown to be independent of immune responses
(39). Thus, it is important to determine the immunogenicity of
anticancer therapies in humans and to identify which myeloid
cells are recruited by chemotherapy.
Some evidence suggests that chemotherapy in humans is asso-
ciated with antigen-specific immune responses (40, 41). Research
on apoptotic antigens conducted previously in our laboratory has
shown that caspase cleavage of self antigens derived from apop-
totic cells facilitates their cross-presentation by DCs (42). Upon
phagocytosis of apoptotic cells, the caspase-fragmented antigens
can be efficiently exported by phagosomes into the cytosol, where
they are processed through the class I-processing pathway and
cross-presented in the form of peptides on class I molecules. In
particular, self antigens, such as lamin B1, actin cytoplasmic 1,
and vimentin, are normally sequestered in cell scaffolds; thus,
they are unavailable for cross-presentation unless they are cleaved
by caspases (43). The CD8+ T-cell responses to these epitopes
are present in chronic viral infections including those caused by
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FIGURE 1 | Cross-presentation of chemotherapy-associated antigens
derived from apoptotic tumor cells leading to anti-tumor immunity.
Tumor cells, upon chemotherapy treatment (i.e., anthracycline), undergo
immunogenic cell death. According to the Kroemer–Zitvogel model, the
immunogenic death (apoptosis, necrosis, autophagy, etc.) of cancer cells
involves a multistep process, including the release of “find-me” signals (such
as fractalkine, nucleotides, and ATP) that attract phagocytes or dendritic cells
(DCs), the expression of “eat-me” signals [such as phosphatidylserine
(PtdSer) and calreticulin] that facilitate recognition by phagocytes or DCs, and,
finally, the release of danger-associated molecular patterns [such as high
mobility group box 1 protein (HMGB1) and other signals described in the text]
that enable dying tumor cells to lose the propensity to induce tolerance and to
stimulate powerful anticancer immune responses. An additional factor that is
involved in the success of the immunogenic chemotherapy may emerge from
the capacity of caspases to cut and release apoptotic cell-associated
antigenic fragments (in red in the figure), thus facilitating their transport from
phagosomes into the cytosol and the processing by DCs (“digest-me”
signals) via the class I-processing pathways [the figure emphasizes the model
suggesting that caspase-cleaved apoptotic fragments are trimmed by
cytosolic proteasomes in the form of peptides and that TAPs transport the
resulting apoptotic self epitopes into the lumen of the endoplasmic reticulum
(ER), where they can bind the appropiate class I molecule]. The final goal of
these multiple checkpoints is to cross-present tumor epitopes and to elicit a
wide repertoire of memory tumor-specific CD8+ T cells in patients undergoing
tumor regression in response to appropriate chemotherapeutic regimes.
These tumor-specific T cells represent a principal tool for discovering
immunogenic tumor antigens by interrogating those responding to highly
purified tumor proteins.
human immunodeficiency virus I and hepatitis C virus (42, 44),
as well as in multiple sclerosis patients (45), and correlate with the
disease progression.
To verify whether chemotherapy-induced apoptosis is
immunogenic in humans, we analyzed OC patients who were
treated with chemotherapy in the adjuvant setting (46) (Figure 1).
To identify the immunogenic chemotherapy-associated antigens
(CAAs), memory T cells from OC patients were interrogated
with proteins isolated from primary OC cells by evaluating their
response to two-dimensional electrophoresis gel-eluted OC pro-
teins. Immunogenic CAAs were then molecularly characterized by
mass spectrometry (MS)-based analysis. Memory T-cell responses
against CAAs derived from apoptotic (but not live) OC cells cor-
related with prolonged survival in response to chemotherapy,
thereby supporting the model of chemotherapy-induced apop-
tosis as an adjuvant of anti-tumor immunity (46). In addition,
memory CD8+ T cells specific for individual OC proteins were
elicited upon cross-presentation of CAAs or whole apoptotic (but
not live) OC cells, suggesting that cross-presentation of tumor
antigens and T-cell responses could contribute to the efficacy of
anticancer chemotherapy. The antigen-specific CD4+ and CD8+
T-cell responses that were originally observed in the screening with
proteins extracted from primary cancer cells were further con-
firmed using corresponding recombinant proteins. It is interesting
to note that antigen-specific CD4+ and CD8+ T cells produced
either IFN-γ or IL-17, which is in line with the recently described
Th17 cell-polarizing infDCs described in human OC cases (17).
MS-based analysis of CAAs showed enrichment for proteins of
stress pathways such as Ras-related protein, heat shock protein
β1, and heat shock protein α-B-crystallin. Taken together, these
data suggest that CAAs correspond not necessarily to tumor cell-
specific antigens but rather to ubiquitous proteins, which, under
normal conditions, are sequestered in cell structures that limit
their processing and presentation to T cells. However, as a result
of the chemotherapy effects, apoptosis of tumor cells can induce
upregulation of a wide range of ubiquitous proteins sufficient for
subsequent processing and presentation by DCs, which in turn
could prime the corresponding specific T cells (Figure 1).
There are many open questions surrounding how DCs can drive
immune responses during chemotherapy in humans and whether
the memory immune response against CAAs plays any role in
preventing tumor relapses. We believe that the identification of
new immune correlates can help in refining a more targeted and
effective anticancer therapy.
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